Open AccessChange in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: A case report
Author(s) -
Ashish Sharma,
R Madhusudhan,
Vidhya Nadahalli,
Shreekant A Damgude,
Selva K Sundaramoorthy
Publication year - 2012
Publication title -
indian journal of ophthalmology/indian journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 51
eISSN - 1998-3689
pISSN - 0301-4738
DOI - 10.4103/0301-4738.95884
Subject(s) - medicine , dexamethasone , diabetic macular edema , bevacizumab , ophthalmology , macular edema , implant , refractory (planetary science) , diabetic retinopathy , surgery , retinal , diabetes mellitus , chemotherapy , endocrinology , physics , astrobiology
We report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA, USA). Patient presented to us with persistent clinically significant macular edema (CSME) in both eyes. Right eye received dexamethasone implant and left eye received two intravitreal bevacizumab injections 1.25 mg/0.05 mL (Avastin®; Genentech Inc., South San Francisco, CA, USA) with an interval of four weeks. After six weeks of follow-up, dexamethasone implant in the right eye showed normal macular thickness whereas persistent macular edema (ME) was found even after second intravitreal bevacizumab injection in the left eye.